189 related articles for article (PubMed ID: 17617037)
21. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
Chen ZD; Wei SM; Cai SL
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
[TBL] [Abstract][Full Text] [Related]
22. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening.
Reissigl A; Klocker H; Pointner J; Fink K; Horninger W; Ennemoser O; Strasser H; Colleselli K; Höltl L; Bartsch G
Urology; 1996 Dec; 48(6A Suppl):62-6. PubMed ID: 8973702
[TBL] [Abstract][Full Text] [Related]
24. Measurement of serum zinc improves prostate cancer detection efficiency in patients with PSA levels between 4 ng/mL and 10 ng/mL.
Li XM; Zhang L; Li J; Li Y; Wang HL; Ji GY; Kuwahara M; Zhao XJ
Asian J Androl; 2005 Sep; 7(3):323-8. PubMed ID: 16110361
[TBL] [Abstract][Full Text] [Related]
25. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Goepel M; Tscholl R
Br J Urol; 1998 Apr; 81(4):532-8. PubMed ID: 9598623
[TBL] [Abstract][Full Text] [Related]
26. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
28. Proper cut-off value of free to total PSA ratio for detection of prostate cancer in Korean men.
Im YJ; Kim JW; Hong SJ; Chung BH
Yonsei Med J; 2004 Oct; 45(5):873-8. PubMed ID: 15515198
[TBL] [Abstract][Full Text] [Related]
29. Why determine only the total prostate-specific antigen, if the free-to-total ratio contains the information?
Eekers DB; Laschet A; de Groot M; Roelofs E; Kester A; Delaere K; Lambin P; van Gils F; Nap M; ten Kate J
Ann Clin Biochem; 2008 May; 45(Pt 3):270-4. PubMed ID: 18482915
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer detection by prostate-specific antigen-related parameters.
Segawa N; Gohji K; Iwamoto Y; Ueda H; Katsuoka Y
Hinyokika Kiyo; 2003 Jul; 49(7):405-10. PubMed ID: 12968483
[TBL] [Abstract][Full Text] [Related]
31. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations.
Veltri RW; Miller MC
Urology; 1999 Apr; 53(4):736-45. PubMed ID: 10197849
[TBL] [Abstract][Full Text] [Related]
32. The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml.
Wu CT; Chuang CK; Chou CC; Chu SH; Chen HW; Chen CS; Chiang YJ; Liao SK
Chang Gung Med J; 2000 Mar; 23(3):142-8. PubMed ID: 15641217
[TBL] [Abstract][Full Text] [Related]
33. Total and free prostate-specific antigen indexes in prostate cancer screening: value and limitation for Japanese populations.
Hara N; Kitamura Y; Saito T; Komatsubara S
Asian J Androl; 2006 Jul; 8(4):429-34. PubMed ID: 16763718
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of the (F/T)/PSA density ratio to detect prostate cancer.
Veneziano S; Pavlica P; Compagnone G; Martorana G
Urol Int; 2005; 74(1):13-8. PubMed ID: 15711102
[TBL] [Abstract][Full Text] [Related]
35. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
36. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
[TBL] [Abstract][Full Text] [Related]
37. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
[TBL] [Abstract][Full Text] [Related]
38. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K
Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
[TBL] [Abstract][Full Text] [Related]
39. The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels.
Pelzer AE; Volgger H; Bektic J; Berger AP; Rehder P; Bartsch G; Horninger W
BJU Int; 2005 Nov; 96(7):995-8. PubMed ID: 16225515
[TBL] [Abstract][Full Text] [Related]
40. Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients.
Battikhi MN
Prostate Cancer Prostatic Dis; 2003; 6(3):256-60. PubMed ID: 12970732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
